Careers

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • HSCA Connect
  • Events
    • 2025 HSCA National Pharmacy Forum
    • Past Events
  • Issues
  • Resources
    • Congressional Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • HSCA Connect
  • Events
    • 2025 HSCA National Pharmacy Forum
    • Past Events
  • Issues
  • Resources
    • Congressional Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News

Comments of the Healthcare Supply Chain Association (HSCA) to FDA on Facilitating Competition and Innovation in the Biological Products Marketplace

September 21, 2018 by admin 2018 Press Releases 0 comments

On behalf of the Healthcare Supply Chain Association (HSCA), thank you for the opportunity to provide comments on the U.S. Food and Drug Administration’s (FDA) “Facilitating Competition and Innovation in the Biological Products Marketplace.”

The ability to safely substitute FDA-approved biosimilars for reference biologics will be critical to realizing the full cost-savings potential of biosimilars and will ensure that patients have timely access to safe, less-costly therapies. HSCA and its member healthcare group purchasing organizations are committed to lowering costs through increased competition and innovation in the healthcare marketplace and have consistently advocated for policies to ensure a pathway to market for biosimilars that prioritizes patient safety and cost savings.

We applaud the FDA for recognizing the value of a competitive and innovative biosimilars marketplace and respectfully offer the following recommendations to promote the swift uptake of biosimilar products:

Read the full comments…

Prev
Next

Related Posts

HSCA Urges DEA to Take Steps to Mitigate Shortages of Injectable Opioids
March 9, 2018

Healthcare Supply Chain Association (HSCA) President and CEO Todd Ebert, R.Ph.,...

Learn more
HSCA Announces Healthcare Cybersecurity Key Considerations
April 17, 2018

The Healthcare Supply Chain Association (HSCA) today announced the release of key...

Learn more
HSCA Comments on DEA Proposed Rule on Opioid Production Limits
May 4, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Comments on FDA Bulk Substance Guidance
May 25, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more

Our Office

Healthcare Supply Chain Association
750 9th Street NW, Suite 650
Washington, DC 20001

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Response to the U.S. Department of Commerce’s Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
    May 8, 2025
  • HSCA Response to the U.S. Trade Representative’s Request for Comments on Unfair and Non-Reciprocal Foreign Trade Practices
    March 12, 2025